Key result
Available risk factors guide SCD assessment in asymptomatic female Brugada syndrome despite lacking female-specific scores.
Why the study?
Due to male predominance and elevated arrhythmic risk in Brugada syndrome, affected females have received less attention, and the association between symptoms and sudden cardiac death risk may not be significant in females.
What is the current evidence for clinical, ECG, and genetic markers in risk stratifying asymptomatic female patients with Brugada syndrome for sudden cardiac death?
What is the current evidence for clinical, ECG, and genetic markers in risk stratifying asymptomatic female patients with Brugada syndrome for sudden cardiac death?
There is a critical need for multinational studies to develop gender-specific risk stratification approaches for asymptomatic female patients with Brugada syndrome.
Answers are grounded in this paper and cite their sources.
Risk factors permit cautious SCD stratification in asymptomatic female Brugada patients; leaves open multinational development of gender-specific scores.
BACKGROUND AND OBJECTIVES: Risk stratification in Brugada syndrome remains a difficult problem. Given the male predominance of this disease and their elevated risks of arrhythmic events, affected females have received less attention. It is widely known that symptomatic patients are at increased risk of sudden cardiac death (SCD) than asymptomatic patients, while this might be true in the male population; recent studies have shown that this association might not be significant in females. Over the past few decades, numerous markers involving clinical symptoms, electrocardiographic (ECG) indices, and genetic tests have been explored, with several risk-scoring models developed so far. The objective of this study is to review the current evidence of clinical and ECG markers as well as risk scores on asymptomatic females with Brugada syndrome. FINDINGS: Gender differences in ECG markers, the yield of genetic findings, and the applicability of risk scores are highlighted. CONCLUSIONS: Various clinical, electrocardiographic, and genetic risk factors are available for assessing SCD risk amongst asymptomatic female BrS patients. However, due to the significant gender discrepancy in BrS, the SCD risk amongst females is often underestimated, and there is a lack of research on female-specific risk factors and multiparametric risk scores. Therefore, multinational studies pooling female BrS patients are needed for the development of a gender-specific risk stratification approach amongst asymptomatic BrS patients.
No takes yet. Share an insight, caveat, or question.
Leung et al. (2023) conducted a review in Brugada syndrome. Risk stratification markers was evaluated on Sudden cardiac death risk. Clinical, electrocardiographic, and genetic risk factors are available for assessing SCD risk in asymptomatic female Brugada syndrome, but female-specific scores are lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: